BRAF and neoplasm: In this context, two clinical trials were developed that aimed to investigate the combination treatment of dabrafenib and trametinib in adult cancer patients harboring a BRAF V600 mutation, regardless of tumor histology: the Rare Oncology Agnostic Research (ROAR) trial [95] and the National Cancer Institute’s Molecular Analysis for Therapy Choice (NCI-MATCH/EAY-131) trial [96].